Sfoglia per AUTORE
PANTANO F
Collezione AOU San Luigi di Orbassano
Items : 2
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1?50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. in Journal for immunotherapy of cancer / J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674.
2025
AOU San Luigi di Orbassano
AOU Novara
AOU San Luigi di Orbassano
AOU Novara
Wakelee H; Garassino M; Peters S; Takada K; Naqash AR; Torri V; Hejleh TA; Ferrara R; Aerts JGJV; Aboubakar Nana F; Dingemans AM; Biello F; Rogado J; Moliner L; Beninato T; Lo Russo G; Servetto A; Mezquita L; Gorría T; Minuti G; Bennati C; Tonini G; Cortinovis DL; Agustoni F; Majem M; Baena J; Macerelli M; Monnet I; O'Reilly D; et alii...
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. in Oncotarget / Oncotarget. 2015 May 20;6(14):12520-8. doi: 10.18632/oncotarget.3724.
2015
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Iuliani M; Pantano F; Buttigliero C; Fioramonti M; Bertaglia V; Vincenzi B; Zoccoli A; Ribelli G; Tucci M; Vignani F; Berruti A; Scagliotti GV; Tonini G; Santini D;